CS
Candriam SCA Portfolio holdings
AUM
$17.3B
1-Year Return
21.68%
This Quarter Return
+5.62%
1 Year Return
+21.68%
3 Year Return
+102.54%
5 Year Return
+176.54%
10 Year Return
+489.52%
AUM
$16.5B
AUM Growth
+$861M
(+5.5%)
Cap. Flow
-$376M
Cap. Flow
% of AUM
-2.28%
Top 10 Holdings %
Top 10 Hldgs %
30.08%
Holding
747
New
44
Increased
335
Reduced
212
Closed
49
Top Buys
| 1 |
Eli Lilly
LLY
|
+$68M |
| 2 |
Qualcomm
QCOM
|
+$56.3M |
| 3 |
Nu Holdings
NU
|
+$53.7M |
| 4 |
Amazon
AMZN
|
+$49M |
| 5 |
Banco Macro
BMA
|
+$43.2M |
Top Sells
| 1 |
Vipshop
VIPS
|
+$599M |
| 2 |
Apple
AAPL
|
+$46.1M |
| 3 |
Adobe
ADBE
|
+$41.4M |
| 4 |
Starbucks
SBUX
|
+$30M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$28.3M |
Sector Composition
| 1 | Technology | 33% |
| 2 | Healthcare | 27.47% |
| 3 | Financials | 9.69% |
| 4 | Consumer Discretionary | 7.72% |
| 5 | Industrials | 6.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Analog Devices
ADI
$122B
| $13.1M | 0.08% |
57,354
-21,626
| -27% | -$4.94M |
|
227
Cardinal Health
CAH
$35.9B
| $12.9M | 0.08% |
131,585
-6,239
| -5% | -$613K |
|
228
Ally Financial
ALLY
$12.7B
| – | – |
0
| – | – |
|
229
Texas Instruments
TXN
$169B
| $12.7M | 0.08% |
65,112
+3,932
| +6% | +$765K |
|
230
Broadridge
BR
$29.7B
| $12.6M | 0.08% |
63,962
-28,795
| -31% | -$5.67M |
|
231
Essential Utilities
WTRG
$10.8B
| $12.3M | 0.07% |
329,150
+43,048
| +15% | +$1.61M |
|
232
Arcutis Biotherapeutics
ARQT
$2.08B
| $12.2M | 0.07% |
+1,307,481
| New | +$12.2M |
|
233
Hannon Armstrong Sustainable Infrastructure Capital
HASI
$3.45B
| $12M | 0.07% |
406,614
-240,467
| -37% | -$7.12M |
|
234
Arcellx
ACLX
$3.94B
| $12M | 0.07% |
217,008
-3,000
| -1% | -$166K |
|
235
Celldex Therapeutics
CLDX
$1.55B
| $11.8M | 0.07% |
317,509
| – | – |
|
|
WRK
236
DELISTED
WestRock Company
WRK
| $11.7M | 0.07% |
233,171
+88,895
| +62% | +$4.47M |
|
237
Legend Biotech
LEGN
$6.39B
| $11.6M | 0.07% |
261,035
+40,003
| +18% | +$1.77M |
|
238
Olema Pharmaceuticals
OLMA
$520M
| $11.5M | 0.07% |
1,058,673
+705,655
| +200% | +$7.63M |
|
239
Labcorp
LH
$23B
| $11.5M | 0.07% |
56,283
+2,558
| +5% | +$521K |
|
240
Citigroup
C
$176B
| $11.3M | 0.07% |
177,800
+13,851
| +8% | +$879K |
|
|
VRNA
241
Verona Pharma
VRNA
$9.19B
| $11.2M | 0.07% |
+772,997
| New | +$11.2M |
|
242
Rhythm Pharmaceuticals
RYTM
$6.63B
| $11.1M | 0.07% |
+271,398
| New | +$11.1M |
|
243
ITT
ITT
$13.5B
| $11.1M | 0.07% |
85,910
| – | – |
|
244
Caterpillar
CAT
$198B
| $11M | 0.07% |
33,164
+66
| +0.2% | +$22K |
|
245
Simon Property Group
SPG
$59.6B
| $10.7M | 0.07% |
70,673
+49,806
| +239% | +$7.56M |
|
246
Vera Therapeutics
VERA
$1.58B
| $10.6M | 0.06% |
293,760
+185,760
| +172% | +$6.72M |
|
247
Immunocore
IMCR
$1.85B
| $10.6M | 0.06% |
313,423
+124,417
| +66% | +$4.22M |
|
248
Ameresco
AMRC
$1.28B
| $10.6M | 0.06% |
368,059
-169,968
| -32% | -$4.9M |
|
249
Guardant Health
GH
$7.5B
| $10.6M | 0.06% |
366,145
-99,992
| -21% | -$2.89M |
|
250
MoonLake Immunotherapeutics
MLTX
$3.88B
| $10.5M | 0.06% |
239,000
| – | – |
|